APM
NASDAQAptorum Group Limited
Price$0.84+0.03 (+3.51%)
2026-03-102026-06-11
News · 26 weeks20+33%
2025-12-142026-06-07
Mix1190d
- SEC Filings9(82%)
- Other2(18%)
Latest news
25 items- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR BiosciencesNEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases. The approval by Aptorum Group's shareholders represents a significant milestone toward completing the previously announced all-stock merger transaction, pursuant to which DiamiR will become a wholly owned subsidiary of Aptorum Group. Diam
- SECSEC Form 424B3 filed by Aptorum Group Limited424B3 - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form EFFECT filed by Aptorum Group LimitedEFFECT - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form EFFECT filed by Aptorum Group LimitedEFFECT - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form S-4/A filed by Aptorum Group LimitedS-4/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form S-4/A filed by Aptorum Group LimitedS-4/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 20-F filed by Aptorum Group Limited20-F - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Aptorum Group Limited6-K/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of PennsylvaniaNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyHong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement. During this period, Aptorum Group Limited intends to evaluate all available options to restore comp
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's DiseaseNEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. ("INB"), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testin
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form S-4/A filed by Aptorum Group LimitedS-4/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form F-3 filed by Aptorum Group LimitedF-3 - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 424B5 filed by Aptorum Group Limited424B5 - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Aptorum Group Limited6-K/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form EFFECT filed by Aptorum Group LimitedEFFECT - Aptorum Group Ltd (0001734005) (Filer)
- PRDiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 ConferenceNEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. Details
- SECSEC Form DEL AM filed by Aptorum Group LimitedDEL AM - Aptorum Group Ltd (0001734005) (Filer)
APM FAQ
6 questionsWhat does Aptorum Group Limited do?
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it...Where does APM stock trade?
Aptorum Group Limited (APM) is listed on NASDAQ.What sector and industry is APM in?
Aptorum Group Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aptorum Group Limited go public?
Aptorum Group Limited (APM) completed its IPO in 2018.What companies are similar to APM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare APM side-by-side with any of them on Quantisnow.How can I track APM on Quantisnow?
Quantisnow aggregates Aptorum Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APM to receive live email and push alerts on every new disclosure.